OPERA-01: A randomized, open-label, phase 3 study of palazestrant (OP-1250) monotherapy vs standard-of-care for ER+, HER2- advanced or metastatic breast cancer patients after endocrine therapy and CDK4/6 inhibitors.

Authors: Barbara Pistilli, Joohyuk Sohn, Peter Schmid, Meritxell Bellet, Lucia Del Mastro, Jane Lowe Meisel, Arlene Chan, Elisabeth de Kermadec, Lianqing Zheng, Heather L. McArthur

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps1131

Source: Full article

---

Abstract

TPS1131